Kelly Godby

Aug 24, 2023 | onlinelibrary.wiley.com | Laura Joiner |Susan Bal |Kelly Godby |Luciano Costa

To the Editor: B-cell maturation antigen (BCMA) expressed in B-cells, normal plasma cells and multiple myeloma (MM) cells has emerged as a novel target for therapy in relapsed or refractory multiple myeloma (RRMM). The United States Federal Drug Administration (FDA)-approved BCMA targeting therapies now include teclistamab,1 ciltacabtagene autoleucel, and idecabtagene vicleucel.